-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-522914-22-00
3
2026-02-11
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
-
2025-520638-53-00
5
2026-02-09
Severe primary dysmenorrhea
-
2024-519505-35-00
5
2026-02-02
hepatocellulaR carcinoma
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515023-11-00
5
2026-01-22
Advanced Clear Cell Renal Cell Carcinoma
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2022-501902-36-00
5
2026-01-15
spina bifida
-
2024-511084-28-00
11
2026-01-12
Hypertrophic Cardiomyopathie
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2024-511437-35-00
10
2026-01-05
Patients aged 18-65 years old with newly diagnosed previously untreate
-
2022-501557-36-00
4
2025-12-19
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
-
2025-521155-23-00
4
2025-12-19
Pulmonary Arterial Hypertension
-
2024-518385-26-01
5
2025-12-18
Polymyalgia Rheumatica (PMR)
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-516789-13-00
6
2025-12-15
Severe asthma
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-519971-25-00
5
2025-12-03
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-517411-73-00
6
2025-11-12
Patient with medium or high risk for pneumococcal invasive infection